News

Tom Ryder Joins Focused Ultrasound Foundation Board of Directors

CHARLOTTESVILLE, VA – Thomas O. Ryder, an investor, entrepreneur, and retired corporate executive, was elected to the Focused Ultrasound Foundation’s Board of Directors at their March 1 meeting.

Ryder has served as Chairman and CEO of the Reader’s Digest Association and President of American Express’s Travel Related Services International, Merchant Services Worldwide, and American Express Publishing Worldwide divisions.

He has experience in the publishing industry, having worked at Time Inc., CBS, and Education Today Company, Inc. where he was co-founder and CEO.

Ryder has also served on numerous boards, including at Amazon for 20 years, during which time he was audit committee chairman and the first lead independent director.

Other previous board appointments have included Starwood Hotels, RPX Corporation, Startek Corp, American Express International Bank, and Virgin Mobile – where he was Chairman.

He is also a prolific writer on the subjects of food and wine.

“Tom brings his unsurpassed skills and experience to the Foundation’s leadership team,” said Foundation Chairman Neal F. Kassell, MD. “He will help to facilitate our efforts to overcome barriers and take advantage of opportunities to shorten the time for focused ultrasound to become a global standard of care.”

Ryder is also an essential tremor patient who underwent focused ultrasound therapy for the disorder in 2021.

“Focused ultrasound fixed a major problem I had with essential tremor and changed my life,” he explains. “I truly hope my tenure on the Foundation Board of Directors will give me the opportunity to share that miracle with others in similar need.”

Read more here.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin